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INTRODUCTION: Idiopathic Pulmonary Hemosiderosis (IPH) is an extremely rare lung disease characterized by diffuse alveolar hemorrhage (DAH) and accumulation of hemosiderin in the lungs. IPH commonly affects children.
Although the exact incidence and prevalence are unknown, estimated yearly incidence in Swedish children from 1960-1979 was 0.24 per one million children.1 The disease clinically manifests as a triad of hemoptysis, diffuse
pulmonary infiltrates, and iron deficiency anemia. Recurrent alveolar bleeding may eventually produce pulmonary hemosiderosis and fibrosis. The etiology of IPH is unknown. However, the response to immunosuppressive therapy
suggests that immune processes may be involved. It appears that a structural defect in the alveolar capillaries, either in the alveolar basement membrane or in the alveolar endothelial cell, may predispose to the condition.1-5 The
accumulation of neutrophils in the alveoli also may play a role.7 Here we report a case where the patient was found to have IPH, that presented with DAH accompanied by clinical signs and symptoms of iron deficiency anemia and
diffuse pulmonary infiltrates on imaging.

Case Report

Discussion

History of Present Illness: A 21-year-old female with past medical history of asthma, vitamin B12
deficiency anemia with iron deficiency anemia, hyperthyroidism and tobacco abuse presented to an Outside
Hospital System with shortness of breath, fatigue, and recurrent hemoptysis worsening over the past six months.
The patient was transferred from current incarceration. Six months previous, the patient was initially admitted
to hospital for shortness of breath and fatigue. The patient was found to have profound anemia with hemoglobin
of 4.4 g/dL and responded to four units of packed red blood cells. Initial CT Scan of the Chest showed patchy
bilateral alveolar infiltrates involving left upper lobe, left lower lobe, and right lower lobe (Figures 1 and 2). The
patient was discharged and did not follow-up as an outpatient with Pulmonology as her hemoptysis improved,
but did receive intravenous iron and Vitamin B12 injections as outpatient with Hematology. She re-presented to
hospital two months later with recurrent non-massive hemoptysis, again with hemoglobin level of 4.4 g/dL. She
responded again to four units of packed red blood cells. Pulmonology was consulted and
patient elected to pursue follow-up as an outpatient, but was lost to follow-up secondary
to incarceration. During incarceration, patient followed with physician to county jail, but
no follow-up occurred. She presented to outside hospital system from incarceration with
symptoms of severe lightheadedness and non-massive recurrent hemoptysis. She was
given 1 unit of packed red blood cells and underwent fiberoptic bronchoscopy, which
showed alveolar hemorrhage. She was subsequently transferred to Lehigh Valley HospitalCedar Crest campus for further management. Her hemoptysis was continuing to occur up Figure 1. Coronal view of initial
chest CT showing pulmonary
to five spoonfuls on a daily basis and described as dark-red, purple-brown in color. The
bilateral infiltrates.
patient reported mild wheezing preceding hemoptysis. She denied fevers, chills, chest
pain, epistaxis, menorrhagia, abdominal pain, nausea, vomiting, hematemesis, melena, and
hematochezia.
Hospital Course: Patient was admitted to medical/surgical floor. On physical exam,
she was afebrile, heart rate was 100 per minute and regular, blood pressure was 118/84
mmHg and oxygen saturation of 94% on room air. Auscultation of the lungs revealed
intermittent wheezing and crackles bilaterally. She had an initial hemoglobin of 7.5 g/dL,
5,500 WBC per mcL and platelets 246,000 per mcL. Her TSH was less than 0.022 µIU/
L with normal free T4 and T3 levels. A CT scan of the chest revealed bilateral infiltrates.
Figure 2. Axial view of initial
She was placed on intravenous azithromycin for previous elevated Mycoplasma IgM and
chest CT showing bilateral
IgG serum titers. The patient underwent a transthoracic echocardiogram showing normal
pulmonary infiltrates.
left ventricular systolic function with normal regional wall motion and ejection fraction
of sixty percent. Broncho-alveolar lavage cultures from bronchoscopy were negative for
acid-fast bacilli. Serologies were negative for anti-nuclear antibodies, anti-neutrophil
cytoplasmic antibodies, anti-glomerular basement membrane antibodies, HIV, QuantiferonTuberculosis Gold assay, Coombs test, and antiphospholipid antibody. Cardiothoracic
surgery was consulted and the patient ultimately underwent thorascopic wedge biopsies of
the right upper, middle, and lower lobes. Pathology demonstrated abundant hemosiderin
deposition within the alveolar macrophages and blood vessel walls, consistent with IPH.
There was no evidence of capillaritis, vasculitis, pulmonary hypertension, or granulomatous
Figure 3. Follow up at 8
months. Coronal view of chest
inflammation. The patient received prednisone (40 mg/day) and Bactrim (1 tab 3 times
CT scan showing resolution of
weekly). Her hemoptysis improved with prednisone therapy. The patient was transferred
infiltrates after corticosteroid
treatment.
to Temple University Hospital for a second opinion in stable condition (Figure 3).

This case report describes a patient with IPH, who presented with signs and symptoms of non-massive
recurrent hemoptysis and infiltrates on chest imaging as well as iron deficiency anemia. In fact, histopathology
demonstrated abundant hemosiderin deposition within the alveolar macrophages and blood vessel walls,
consistent with anemia and a diagnosis of IPH.
The exact incidence and prevalence of IPH are largely unknown. Eighty percent of cases of IPH occur in children,
generally manifesting before 10 years of age.8,9 In adults, most cases are recognized before 30 years of age.
Patients classically present with a triad of recurrent or chronic pulmonary symptoms (cough, dyspnea, wheeze,
hemoptysis), pulmonary infiltrates on CXR, and iron-deficiency anemia. Our patient had all three components to
suspect IPH.
A diagnosis of IPH is based on exclusion of other causes of intrapulmonary hemorrhage and systemic diseases.
In the absence of systemic disease, findings of hemosiderin-laden macrophages in bronchoscopic lavage or
gastric aspirate/sputum along with chronic pulmonary symptoms lead to diagnosis of IPH. Lung biopsy is the
gold standard for diagnosis. It is important to exclude pulmonary capillaritis, which is a cause of DAH. Pulmonary
capillaritis is a small-vessel vasculitis, which can occur as an isolated condition or in association with multiple
systemic vasculitides. Isolated DAH without identifiable causation or associated disease is referred to as IPH.10
Daily oral corticosteroids or weekly intravenous pulse of methylprednisolone is commonly used in the
induction treatment of IPH. Other immunosuppressive agents such as azathioprine, cyclophosphamide, and
hydroxychloroquine have also been used alone or in combination with oral corticosteroids.11-15 Low-dose oral
corticosteroids, azathioprine, or methotrexate are used in maintenance phase. Aggressive treatment with the
use of corticosteroids and immunosuppressive agents are associated with a prolonged survival and improved
prognosis.16 Long-term low-dose corticosteroid therapy was also reported to result in a milder disease course and
prevent bleeding crisis.17 Data from Saeed et al. report patients today have eighty-six percent survival beyond
five years of diagnosis. However, due to the lack of large patient series and inadequate follow-up in previous
studies, the prognosis of IPH remains unclear.18
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